Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.

Mansoor Raza Mirza,Bradley J. Monk,Marta Gil-Martin,Lucy Gilbert,Ulrich Canzler,Philippe Follana,Justin Waters,Frédéric Kridelka,Tally Levy,Benedict B. Benigno,Kathrine Woie,Diane Provencher,Hans-Joachim Lueck,Antonio Casado Herráez,Anne Lesoin,Joseph Buscema,Kristina Hellman,Bj Rimel,Sebastien Hazard,Ursula A. Matulonis

Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.

2017

5517Background: Therapeutic paradigms for recurrent OC vary by geography. Maintenance following response to platinum-based chemotherapy (Plat) is standard in Europe, whereas in the US maintenance i...

Keywords:

Oncology
Progression-free survival
Pathology
Recurrent Ovarian Cancer
Internal medicine
Chemotherapy
Medicine
in patient
partial response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations